FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003214569> ?p ?o ?g. }

• W2003214569 endingPage "246" @default.
• W2003214569 startingPage "225" @default.
• W2003214569 abstract "CNS Drug ReviewsVolume 4, Issue 3 p. 225-246 Free Access Preclinical and Pharmacological Studies of AG284, a Soluble HLA-DR2:Myelin Basic Protein Peptide Complex for the Treatment of Multiple Sclerosis Edward G. Spack, Corresponding Author Edward G. Spack Anergen, Inc., Redwood City, CA, USADr. E. G. Spack, Megabios Corp., 863A Mitten Rd., Burlin-game, CA 94010, USA.Search for more papers by this authorNancy G. Wehner, Nancy G. Wehner Anergen, Inc., Redwood City, CA, USASearch for more papers by this authorJeffrey L. Winkelhake, Jeffrey L. Winkelhake Anergen, Inc., Redwood City, CA, USASearch for more papers by this author Edward G. Spack, Corresponding Author Edward G. Spack Anergen, Inc., Redwood City, CA, USADr. E. G. Spack, Megabios Corp., 863A Mitten Rd., Burlin-game, CA 94010, USA.Search for more papers by this authorNancy G. Wehner, Nancy G. Wehner Anergen, Inc., Redwood City, CA, USASearch for more papers by this authorJeffrey L. Winkelhake, Jeffrey L. Winkelhake Anergen, Inc., Redwood City, CA, USASearch for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3458.1998.tb00066.xCitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Blascyzk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789– 790. 2 Boggs JM, Chang N-H, Groundalkar A, Hashim GA. Stimulation of tolerization of an anti-myelin basic protein T lymphocyte line with membrane fragments from antigen presenting cells. Cell Immunol 1992; 143: 23– 40. 3 Bond AP, Corlett L, Curnow SJ, Spack E, Willcox N, Newsom-Davis J. Diverse patterns of unresponsiveness in an acetylcholine receptor-specific T-cell clone from a myasthenia gravis patient after engaging the T-cell receptor with three different ligands. J Neuroimmunol 1998; 82: 182– 190. 4 Boggs JM, Chang NH, Groundalkar A, Hashim GA. Stimulation or tolerization of an anti-myelin basic protein T lymphocyte line with membrane fragments from antigen-presenting cells. Cell Immunol 1992; 143: 23– 40. 5 Brock S, Gijbels K, Allegretta M, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379: 343– 346. 6 Claus R, Werner H, Schulze H, Walzel H, Friemel H. Are soluble monocyte-derived HLA class II molecules candidates for immunosuppressive activity Immunol Lett 1990; 26: 203– 210. 7 Critchfield JM, Lenardo MJ. Antigen-induced programmed T cell death as a new approach to immune therapy. Clin Immunol Immunopathol 1995; 75: 13– 19. 8 Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T-cell responses. Crit Rev Immunol 1997; 17: 89– 118. 9 Dresser DW. Specific inhibition of antibody production. I. Protein over-loading paralysis. Immunology 1962; 5: 161– 168. 10 Fuji Y, Lindstrom J. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. J Immunol 1988; 140: 1830– 1837. 11 Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586– 6590. 12 Goodkin DE, Ransohoff RM, Rudick RA. Experimental therapies for multiple sclerosis: Current status. Clev Clinic J Med 1992; 59: 63– 74. 13 Grosse-Wilde H, Blascyzk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tiss Antigens 1992; 39: 74– 77. 14 Jendro MK, Gornzy JJ, Weyand CM. Structural and functional characterization of HLA-DR molecules circulating in serum. Autoimmunity 1991; 8: 289– 296. 15 Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T-cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165: 302– 319. 16 Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CCA, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis: Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993; 92: 2602– 2608. 17 Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155– 157. 18 Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998; 101: 725– 730. 19 Manning CH, Heise ER. Biochemical analysis of class I and class II MHC antigens in cynomolgus macaques by one-dimensional isoelectric focusing. Tiss Antigens 1991; 37: 56– 65. 20 Martin R, Jaraquemada D, Flerlage M, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990; 145: 540– 548. 21 Miller A, Lider O, Roberts AB, Sporn M, Weiner HL. Suppressor T cells generated by oral tolerance to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-β following antigen specific triggering. Proc Natl Acad Sci USA 1992; 89: 421– 425. 22 Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution for five therapeutic proteins. Pharm Res 1991; 8: 1351– 1359. 23 Nau GJ, Moldwin RL, Lancki DW, Kim D, Fitch FW. Inhibition of IL-2-driven proliferation of murine T-lymphocyte clones by supraoptimal levels of immobilized anti-T-cell receptor monoclonal antibody. J Immunol 1987; 139: 114– 122. 24 Nicolle MW, Nag B, Sharma SD, et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994; 93: 1361– 1369. 25 Olerup O, Hillert J. HLA class II associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tiss Antigens 1991; 38: 1– 15. 26 Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183– 187. 27 Ott M, Seidl C, Westhoff U, et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tiss Antigens 1998; 51: 301– 304. 28 Pette M, Fujita K, Wilkinson D, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87: 7968– 7972. 29 Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40: 1770– 1776. 30 Quill H, Schwartz RH. Stimulation of normal inducer T-cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987; 138: 3704– 3712. 31 Salvetti M, Ristori G, D'Amato M, et al. Predominant and stable T-cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis. Eur J Immunol 1993: 23: 1232– 1239. 32 Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 1998; 160: 1532– 1538. 33 Schwartz RH. Models of T-cell anergy: is there a common molecular mechanism J Exp Med 1996; 184: 1– 8. 34 Sharma SD, Nag B, Su X-M, et al. Antigen- specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci USA 1991; 88: 11465– 11469. 35 Spack EG, McCutcheon M, Corbelletta N, Nag B, Passmore D, Sharma SD. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II: acetylcholine receptor peptide complexes. J Autoimmun 1995; 8: 787– 807. 36 Spack EG. Induction of apoptosis in autoreactive T cells with soluble MHC II:peptide complexes. In: W Hori, ed. Apoptosis: Practical applications and novel therapies. Southborough , MA : IBC's Library Series, 1997: 2.4.1– 2.4.26. 37 Spack EG. Drugs in development for the treatment of multiple sclerosis: Antigen-specific therapies. Exp Opin Invest Drugs 1996; 5: 1331– 1348. 38 Spack EG. Antigen-specific therapies for the treatment of multiple sclerosis: A clinical trial update. Exp Opin Invest Drugs 1997; 6: 1715– 1727. 39 Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry. Proc Natl Acad Sci USA 1996; 93: 2253– 2256. 40 Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165– 173. 41 Tiwari JL, Terasaki PI. HLA and disease associations. New York : Springer Verlag, 1985. 42 Trotter J, Sriram S, Rassenti L, Chou CH, Fritz RB, Steinman L. Characterization of T cell lines and clones from SJL/J and (BALB/c × SJL/J)F1 mice specific for myelin basic protein. J Immunol 1985; 134: 2322– 2327. 43 Valli A, Sette A, Kappos L, et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993; 91: 616– 628. 44 Varma RK, Kaushal R, Junnarkar AY, et al. Polysorbate 80: A pharmacological study. Drug Res 1985; 35: 804– 808. 45 Webb S, Sprent J. Downregulation of T-cell responses by antibodies to the T-cell receptor. J Exp Med 1987; 165: 584– 589. 46 Weyand CM, Jendro M, Goronzy JJ. Soluble HLA-DR molecules in patients with HLA class II versus class I associated disorders. Autoimmunology 1991; 8: 281– 287. 47 Wucherpfenig KW, Zhang J, Witek C, et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994; 152: 5581– 5592. Citing Literature Volume4, Issue3September 1998Pages 225-246 ReferencesRelatedInformation" @default.
• W2003214569 created "2016-06-24" @default.
• W2003214569 creator A5056587271 @default.
• W2003214569 creator A5068880524 @default.
• W2003214569 creator A5083241841 @default.
• W2003214569 date "1998-09-01" @default.
• W2003214569 modified "2023-09-24" @default.
• W2003214569 title "Preclinical and Pharmacological Studies of AG284, a Soluble HLA-DR2:Myelin Basic Protein Peptide Complex for the Treatment of Multiple Sclerosis" @default.
• W2003214569 cites W1481073656 @default.
• W2003214569 cites W1490998575 @default.
• W2003214569 cites W1512091369 @default.
• W2003214569 cites W1528603850 @default.
• W2003214569 cites W1567730870 @default.
• W2003214569 cites W1639391087 @default.
• W2003214569 cites W1645637874 @default.
• W2003214569 cites W1967953573 @default.
• W2003214569 cites W1975326909 @default.
• W2003214569 cites W1983558067 @default.
• W2003214569 cites W1990640592 @default.
• W2003214569 cites W1991050163 @default.
• W2003214569 cites W1995089724 @default.
• W2003214569 cites W2000048275 @default.
• W2003214569 cites W2002779814 @default.
• W2003214569 cites W2008065048 @default.
• W2003214569 cites W2013567615 @default.
• W2003214569 cites W2020824441 @default.
• W2003214569 cites W2030087226 @default.
• W2003214569 cites W2044049104 @default.
• W2003214569 cites W2044316391 @default.
• W2003214569 cites W2053620210 @default.
• W2003214569 cites W2057817955 @default.
• W2003214569 cites W2059274025 @default.
• W2003214569 cites W2066711893 @default.
• W2003214569 cites W2069346319 @default.
• W2003214569 cites W2077812123 @default.
• W2003214569 cites W2081395451 @default.
• W2003214569 cites W2082604634 @default.
• W2003214569 cites W2084302549 @default.
• W2003214569 cites W2088437362 @default.
• W2003214569 cites W2090256206 @default.
• W2003214569 cites W2092641111 @default.
• W2003214569 cites W2097093422 @default.
• W2003214569 cites W2099748840 @default.
• W2003214569 cites W2125504851 @default.
• W2003214569 cites W2128707261 @default.
• W2003214569 cites W2145893204 @default.
• W2003214569 cites W2147731454 @default.
• W2003214569 cites W2162250437 @default.
• W2003214569 cites W2163840176 @default.
• W2003214569 cites W2168931543 @default.
• W2003214569 cites W2315449683 @default.
• W2003214569 doi "https://doi.org/10.1111/j.1527-3458.1998.tb00066.x" @default.
• W2003214569 hasPublicationYear "1998" @default.
• W2003214569 type Work @default.
• W2003214569 sameAs 2003214569 @default.
• W2003214569 citedByCount "7" @default.
• W2003214569 countsByYear W20032145692013 @default.
• W2003214569 crossrefType "journal-article" @default.
• W2003214569 hasAuthorship W2003214569A5056587271 @default.
• W2003214569 hasAuthorship W2003214569A5068880524 @default.
• W2003214569 hasAuthorship W2003214569A5083241841 @default.
• W2003214569 hasConcept C169760540 @default.
• W2003214569 hasConcept C185592680 @default.
• W2003214569 hasConcept C203014093 @default.
• W2003214569 hasConcept C25498285 @default.
• W2003214569 hasConcept C2778609137 @default.
• W2003214569 hasConcept C2779281246 @default.
• W2003214569 hasConcept C2780640218 @default.
• W2003214569 hasConcept C2780876595 @default.
• W2003214569 hasConcept C529278444 @default.
• W2003214569 hasConcept C55493867 @default.
• W2003214569 hasConcept C71924100 @default.
• W2003214569 hasConcept C86803240 @default.
• W2003214569 hasConcept C98274493 @default.
• W2003214569 hasConceptScore W2003214569C169760540 @default.
• W2003214569 hasConceptScore W2003214569C185592680 @default.
• W2003214569 hasConceptScore W2003214569C203014093 @default.
• W2003214569 hasConceptScore W2003214569C25498285 @default.
• W2003214569 hasConceptScore W2003214569C2778609137 @default.
• W2003214569 hasConceptScore W2003214569C2779281246 @default.
• W2003214569 hasConceptScore W2003214569C2780640218 @default.
• W2003214569 hasConceptScore W2003214569C2780876595 @default.
• W2003214569 hasConceptScore W2003214569C529278444 @default.
• W2003214569 hasConceptScore W2003214569C55493867 @default.
• W2003214569 hasConceptScore W2003214569C71924100 @default.
• W2003214569 hasConceptScore W2003214569C86803240 @default.
• W2003214569 hasConceptScore W2003214569C98274493 @default.
• W2003214569 hasIssue "3" @default.
• W2003214569 hasLocation W20032145691 @default.
• W2003214569 hasOpenAccess W2003214569 @default.
• W2003214569 hasPrimaryLocation W20032145691 @default.
• W2003214569 hasRelatedWork W1995991167 @default.
• W2003214569 hasRelatedWork W2018855460 @default.
• W2003214569 hasRelatedWork W2062016501 @default.
• W2003214569 hasRelatedWork W2077505288 @default.
• W2003214569 hasRelatedWork W2090613411 @default.
• W2003214569 hasRelatedWork W2166551342 @default.
• W2003214569 hasRelatedWork W2299045175 @default.

• next